Evidence-based hormone therapy: it is not whether, it is how.

The pharmacology of estradiol, progesterone, and testosterone is well established. The question was never whether to compound hormones: it is how to ensure quality and compliance when you do.

When compounding follows USP standards and uses verified, pharmaceutical-grade ingredients, compounded bioidentical hormone therapy (cBHT) is a safe, effective, and essential tool for personalized care.

Separating controversy from truth

The real issue

• Wrong question: “Are compounded hormones safe?”
• Right question: Is the compounding process compliant with USP standards?
• Right question: Are the ingredients pharmaceutical-grade and verified?

The controversy around cBHT is largely misplaced. Much of the debate has been crowded out by fear and regulatory reach, obscuring what actually matters for patient safety: quality control and process compliance.

The pharmacological actions of estradiol, progesterone, and testosterone are extensively documented; these molecules underpin numerous FDA-approved products. The question has never been whether the hormones work: it is whether, when compounded, the process holds to pharmaceutical-quality standards.

The Women's Health Initiative: a closer reading

The watershed moment

To understand today’s landscape, return to 2002. The Women’s Health Initiative (WHI) prompted a panic that led half of all women on hormone therapy to stop within 18 months. The headlines warned of higher risk for breast cancer, heart disease, and stroke.

Two decades of re-analysis tell a different story: the study was deeply flawed, and its conclusions were badly misapplied.

Three flaws that mattered

1. Wrong hormones. WHI used conjugated equine estrogens (from horse urine) and synthetic medroxyprogesterone, not bioidentical hormones. Applying those results to bioidentical estradiol and progesterone is not scientifically valid.
2. Wrong population. Average age was 63, with two-thirds over 60 and many 10–20 years post-menopause. Typical hormone therapy users are 48–52, recently menopausal, and symptomatic.
3. Wrong interpretation. Coverage reported a 26% increase in relative risk instead of 8 cases per 10,000 women in absolute terms. The absolute risk increase was under 0.1% per year.

The 20-year correction

Re-analyzing WHI data by age changed the picture dramatically:

• 30% Lower all-cause mortality for women 50–59 using hormones.
• 60% Lower coronary-calcium risk with estrogen-alone therapy.
• 50K–91K Estimated deaths attributed to estrogen avoidance (2002–2011).

The 2020 NASEM report: a flawed framework

The regulatory weapon

In 2020, the National Academies of Sciences, Engineering, and Medicine (NASEM) issued a report on cBHT concluding there was a “dearth of evidence” for its clinical utility. The FDA commissioned it, and its recommendations would effectively remove cBHT as an option for most patients.

A close reading suggests it was less an objective review than a document built to justify federal control over the practice of compounding.

1. Committee composition. The flaw: No practicing cBHT physicians or compounding pharmacists sat on the committee, which was led by academics with FDA and pharmaceutical ties. The impact: A former FDA anti-compounding official served as both a key presenter and an external reviewer, placing the FDA on both sides of its own question.
2. An invented definition. The flaw: The report defined “clinical utility” to mirror FDA drug-approval standards. The impact: That standard is one personalized medicine cannot meet by design, which preselected the conclusion.
3. A manufactured evidence gap. The flaw: Only 13 studies were reviewed (8 on DHEA) while hundreds of submissions were set aside. The impact: The “dearth of evidence” came from exclusion, not from objective review, and ignored the most commonly prescribed formulations.
4. The wrong regulatory frame. The flaw: Mass-production drug-approval standards were applied to individualized compounding. The impact: In Thompson v. Western States (2002), the Supreme Court held this approach “would not make sense”: the paradigms are incompatible.

The evidence NASEM declined to review

The science

2022 meta-analysis: the direct rebuttal

Published in Menopause, this systematic review answered the “no evidence” claim head-on.

• Safety: No adverse changes in lipids, glucose metabolism, or endometrial thickness.
• Efficacy: Significant improvement in vaginal atrophy symptoms and sexual function.
• Conclusion: A favorable short-term safety profile across 1,800+ patients in controlled trials.

Evidence for specific compounded hormones

Estriol

Vulvovaginal atrophy (VVA)

• Evidence: Multiple clinical studies confirm relief of dryness and painful intercourse.
• Safety: Minimal systemic absorption and a strong safety profile, including for select breast cancer survivors.
• Unmet need: No FDA-approved estriol product exists in the U.S.

Testosterone for women

Hypoactive sexual desire disorder (HSDD)

• Evidence: The 2019 Global Consensus found it effective for postmenopausal women with HSDD, based on an RCT meta-analysis.
• Safety: Improves desire, arousal, and satisfaction via transdermal administration.
• Unmet need: No FDA-approved testosterone product for women exists.

Bi-Est / Tri-Est combinations

Menopausal symptoms

• Evidence: A 36-month prospective study showed significant symptom relief and favorable cardiovascular markers.
• Safety: No adverse events over three years; no adverse change in thrombotic potential.
• Unmet need: Custom ratios are not available commercially.

What patients experience

Real-world outcomes

2020 study: Greene Climacteric Scale results

Real-world data like this captures the lived experience of patients, the day-to-day improvement the trials are pointing at.

When compounding is essential

Medical necessity

• Allergies & sensitivities. Patients allergic to excipients (lactose, gluten, dyes, preservatives) in FDA-approved products need custom formulations.
• Unique dosages & combinations. Precise, individualized dosing or combinations like Bi-Est and Tri-Est that are not commercially available.
• Alternative delivery. Patients who need transdermal creams, sublingual troches, or vaginal suppositories rather than oral medications.
• Unmet medical needs. No FDA-approved products exist for estriol or testosterone for women. Compounding is the only option.

Quality through proper standards

The solution

The path to patient safety is not prohibition. It is rigorous enforcement of quality standards within the existing, appropriate framework for pharmaceutical compounding.

Compliant process

• USP Chapter 795/797: strict adherence to non-sterile compounding standards.
• Licensed professionals: performed by licensed pharmacists in regulated pharmacies.
• State oversight: State Boards of Pharmacy inspection and enforcement.
• Documentation: complete batch records and quality tracking.

Quality API

• FDA-registered sources: all APIs from FDA-registered establishments only.
• Certificate of analysis: verification for every batch of bulk drug substance.
• Pharmaceutical-grade: USP/NF grade ingredients, not “natural” supplements.
• PCAB accreditation: the voluntary gold standard for quality assurance.

Two paradigms, one patient

The philosophical divide

The disagreement is less about science than about philosophy. Two regulatory paradigms are in conflict, and the divide is worth seeing clearly.

Industrial model

FDA drug-approval framework

• Mass production for broad populations
• Billion-dollar Phase III trials
• Standardized dosing and formulations
• Pre-market approval required
• One-size-fits-most

Appropriate for commercial pharmaceuticals.

Personalized model

State pharmacy-board oversight

• Individual patient customization
• USP quality standards (795/797)
• Physician–pharmacist–patient triad
• State board inspection & enforcement
• Tailored to specific needs

Appropriate for personalized compounding.

“It would not make sense to require compounded drugs created to meet the unique needs of individual patients to undergo the testing required for the new drug approval process.”

U.S. Supreme Court, Thompson v. Western States, 2002

Where major organizations stand

The debate

Position of caution

NAMS · Endocrine Society · ACOG

Core concern: limited large-scale RCT data and FDA oversight.

• Minimal federal regulation compared with FDA-approved drugs
• Potential for dosing variability
• Preference for standardized, FDA-approved products
• Concern about patient misinformation

Position of clinical necessity

Alliance for Pharmacy Compounding (APC) · NCPA

Core argument: cBHT is critical and irreplaceable for unmet patient needs.

• The only option for patients with specific medical needs
• Physician autonomy protected by law
• Already regulated by state boards and USP standards
• A growing body of RCT evidence (2022 meta-analysis)

Focus on quality, not prohibition

The path forward

Eliminating cBHT would be a significant intrusion into the physician–patient relationship and a disregard for physician autonomy, principles that are foundational to medical practice and protected by law.

The most patient-centered path is not restriction, but collaboration:

1. Set aside the flawed NASEM report. Stop relying on a biased, methodologically unsound document.
2. Enforce existing quality standards. Strengthen State Board inspection and USP compliance verification.
3. Require API verification. Mandate FDA-registered sources and a certificate of analysis for all bulk ingredients.
4. Promote PCAB accreditation. Encourage voluntary third-party quality certification.
5. Preserve physician autonomy. Protect clinical decision-making for individualized patient care.

Built on rigorous evidence

Research foundation

• 2022 meta-analysis. “Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials”, Menopause journal.
• Independent NASEM analysis. Berkeley Research Group analysis of methodological flaws and bias in the 2020 NASEM report.
• WHI re-analysis. Multiple long-term follow-up studies confirming benefits for women 50–59, published in JAMA and other peer-reviewed journals.
• Patient-reported outcomes. “Compounded bioidentical HRT improves quality of life and reduces menopausal symptoms”, Journal of Prescribing Practice, 2020.

Full bibliography available on request. Claims are supported by peer-reviewed research and independent analysis.